Hepatology:新方法允许一步法诊断HCV感染

2016-06-09 佚名 生物谷

当前诊断丙型肝炎病毒(HCV)感染的标准方法需要两个连续的步骤:用于筛选的HCV抗体测试,随后进行HCV RNA RT-PCR测试来验证病毒血症性HCV(viremic HCV, V-HCV)感染(编者注:即导致病毒血症的HCV感染)。这使得它未最优化、成本高、不方便、耗时和不能够在全球广泛使用或负担得起。HCV核心抗原(HCVcAg)测试有潜力提供一步法诊断HCV感染。然而,它的灵敏度和特异

当前诊断丙型肝炎病毒(HCV)感染的标准方法需要两个连续的步骤:用于筛选的HCV抗体测试,随后进行HCV RNA RT-PCR测试来验证病毒血症性HCV(viremic HCV, V-HCV)感染(编者注:即导致病毒血症的HCV感染)。这使得它未最优化、成本高、不方便、耗时和不能够在全球广泛使用或负担得起。

HCV核心抗原(HCVcAg)测试有潜力提供一步法诊断HCV感染。然而,它的灵敏度和特异性较低限制了它的临床应用。

在一项新的研究中,来自美国加州大学欧文分校的研究人员开发出一种新的HCV抗原酶免疫测定法(HCV-Ags EIA),并利用365种血清样品(其中,176种未发生V-HCV感染,189种发生V-HCV感染)评估了这种一步法诊断V-HCV感染的灵敏度、特异性和实用性。相关研究结果于2016年6月6日在线发表在Hepatology期刊上,论文标题为“A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection”。

首先,研究人员证实在HCV感染期间,除了HCV核心抗原之外,还存在HCV NS3、NS4b和NS5a蛋白。基于此,他们开发出这种新的同时检测这四种HCV蛋白的HCV-Ags EIA方法。

这项研究首次证实血清样品变性导致释放出的HCV抗原以HCV免疫复合物的形式存在,从而降低测试特异性,因此应当不能够用于任何HCV抗原测试,包括所有当前的HCV核心抗原测试。

另一方面,与血清HCV抗体测试和HCV RNA RT-PCR测试的结果相比较,利用未变性的血清样品,这种HCV-Ags EIA测试结果的特异性为99%,灵敏度为100%。

利用未变性的进行过稀释的血清样品进行测试,这种HCV-Ags EIA方法的最低检测限相当于大约150~250 IU/mL的血清HCV RNA水平。

研究人员开发出的这种HCV-Ags EIA方法是高度特异性的和高度灵敏的。利用未变性的血清样品,这种HCV-Ags EIA方法能够可靠地区分V-HCV感染和已得到控制的HCV感染,而且是一步法实现对V-HCV感染的筛选和诊断。

论文作者写道,“慢性HCV感染影响全世界大约1.7亿人,并且与发展为肝硬化和肝细胞癌的风险相关联。尽管卫生专业实践指导方针主张对HCV感染进行筛选,但是最近的研究表明在HCV感染的筛选和诊断方面还存在重大的缺口。”

原始出处

Ke-Qin Hu,Wei Cui.A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection.Hepatology.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-06-11 milkshark

    这个不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-06-11 milkshark

    值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-06-11 ymljack
  7. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-06-11 gwc384
  8. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1903140, encodeId=480a190314060, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Oct 16 08:12:00 CST 2016, time=2016-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105787, encodeId=b7be105e87a0, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 21:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105586, encodeId=e908105586ed, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 14:25:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89377, encodeId=5944893e71b, content=这个不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89378, encodeId=4e9c893e8a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Sat Jun 11 08:22:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257633, encodeId=c2a0125e63308, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426652, encodeId=55d214266524d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618968, encodeId=d0e3161896849, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jun 11 05:12:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89189, encodeId=785289189b8, content=期待临床推广应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160610/IMG575A14CF7A53B3567.jpg, createdBy=88871326528, createdName=598450530, createdTime=Fri Jun 10 09:17:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
    2016-06-10 598450530

    期待临床推广应用

    0

相关资讯

罗氏:FDA批准非小细胞肺癌(NSCLC)血液样本基因检测试剂盒

瑞士制药巨头罗氏(Roche)近日宣布,美国食品和药物管理局(FDA)已批准cobas EGFR Mutation Test v2(cobas EGFR突变检测试剂盒v2),这是一款以血液为基础的、用于抗癌药特罗凯(Tarceva,通用名:erlotinib,厄洛替尼)的伴随诊断试剂盒。值得一提的是,这是FDA批准的首个以血液为基础、用于检测非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGF

穿着仅供研究外衣 过敏原诊断试剂无证上岗

穿着仅供研究外衣 过敏原诊断试剂无证上岗 中国青年报记者调查发现,北京、上海、南京等地的多家知名医院、研究所,近年来曾将本应“仅供研究”的未经注册医疗器械,用于临床诊断。 这些医疗器械,均为著名外企赛默飞世尔科技(中国)有限公司(以下简称“赛默飞公司”)Phadia过敏原诊断试剂中的一部分产品。该产品属于按医疗器械管理的体外诊断试剂,且为风险程度最高的第三类产品。按照规定,在未获得医疗

盘点:体外诊断试剂(IVD)七大违规情况

体外诊断试剂(IVD)涉及诊断、治疗方案选择、疗效评价等疾病诊治的全过程,需求量大,关系人民群众的切身利益。国家总局先后印发了《关于印发体外诊断试剂抽验工作方案的通知》《关于印发体外诊断试剂风险排查工作方案的通知》《关于印发体外诊断试剂专项整治工作方案的通知》《国家总局办公厅关于印发体外诊断试剂质量评估和综合治理工作方案的通知》等文件。 一、生产、销售、使用未取得医疗器械注册证的体外诊断试

《医疗器械临床试验质量管理规范》今日实行

为加强医疗器械临床试验监督管理,维护医疗器械临床试验过程中受试者权益,保证医疗器械临床试验过程规范,国家食品药品监督管理总局、国家卫生计生委联合发布的《医疗器械临床试验质量管理规范》今起施行。 规范提出,在受试者参与临床试验前,研究者应当充分向受试者或者无民事行为能力人、限制民事行为能力人的监护人说明临床试验的详细情况,包括已知的、可以预见的风险和可能发生的不良事件等。申办者对发生与试验相关

喘口气就知道有没有病,竟然有这样的传感器

富士通研究所开发出了可从呼气中提取与生活方式病有关的特定成分,并在短时间内检测出浓度的便携式呼气传感器。该技术“可像体温计一样轻松地”对应该接受精密检查的人进行筛查,从而及早发现生活方式病。目标是2018年度达到实用化。 开发小组着眼的是跟肝脏代谢及胃癌危险因素——幽门螺杆菌感染有关的氨气。利用溴化铜吸附氨气的性质,开发出了能检测出呼气中的极微量氨气的传感器,检测氨气的灵敏度是丙酮等其他气

林金明:微流控芯片上基于核酸适配体的蛋白质检测方法研究

2016(第四届)先进体外诊断技术峰会于3月26日在上海胜利召开。此次会议邀请了国内外众多体外诊断方面的专家学者,以及在体外诊断领域取得不俗业绩的企业家代表。 会议的第二天来自清华大学化学系的林金明教授做了精彩的演讲。演讲主要围绕着微流控芯片上给予核酸适配体的蛋白质检测方法研究。 演讲中林教授提到。微流控芯片技术可以继承或基本继承化学和生物等领域中所涉及的样品制备、反应、分离、检测等基本